Complement protein C5a is recognized as an important component of the alternative complement pathway. Bioanalytical challenges have been posed in proper quantitation of free C5a due to interference from its precursor, C5. Additionally, free therapeutic target quantitation can be difficult due to effects of sample dilution and prolonged sample incubation when therapeutic is used as capture reagent. Gyrolab technology enables quantitation of free target analyte with minimal sample dilution and rapid sample incubations, thus enabling in vitro results that are more representative of in vivo pharmacodynamics. When coupled with strategic sample pretreatment, Gyrolab offers an opportunity to quantitate free C5a in human plasma with an assay that vastly diminishes C5 interference. A Gyrolab assay for the quantitation of free C5a in human plasma was developed and validated. Validation results confirmed that proper sample pretreatment and use of the Gyrolab platform yield accurate and reliable results. Due to the advantages that it provides, Gyrolab has become our default technology of choice for quantitation of free target.
This educational webinar will be helpful for those involved with:
- Ligand binding assays interested in maximizing performance and productivity
- Free target biomarker studies and solving for overestimation of target
Mark Dysinger, M.S.
Development Scientist III
Mark Dysinger is a development scientist at Alexion Pharmaceuticals in New Haven, Connecticut. In his role, he is a bioanalytical project representative for novel rare disease drug therapies. He is also heavily involved in relevant method development, assay validation, and sample analysis for both preclinical and clinical trials. Mark is a member of the AAPS Emerging Technologies Action Planning Committee, a member of the scientific advisory board at AIT Biosciences, and an abstract and manuscript reviewer for multiple meetings and publications. He holds a Bachelor’s degree in Zoology from the University of Maine, and a Master of Science degree in biotechnology from the University of Maryland University College. With more than 20 years of experience, Mark is vested in furthering industry progress in bioanalysis.
Cost: No Cost!